# US 2003/0223986 A1 · Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223986 A1
- Document ID: US20030223986A1
- Status: Published application
- Kind: A1
- Application number: 10/400,897
- Filed: 2003-03-27
- Published: 2003-12-04
- Earliest claimed: 2000-01-18
- Assignees: AstraZeneca AB, a Swedish corporation
- Inventors: John C. Smith; Rakesh Anand; John E.N. Morten
- Web page: https://patentgrep.com/patent/US20030223986A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention relates to polymorphisms in the human pyruvate dehydrogenase complex E2 (PDH E2 or PDC E2) gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the PDH E2 gene, and to the use of PDH E2 polymorphism in the diagnosis and treatment of. diseases in which modulation of pyruvate dehydrogenase activity could be of therapeutic benefit, such as diabetes, asthma, obesity, sepsis and peripheral vascular disease. In particular, the invention is based on the discovery of two single nucleotide polymorphisms (SNPs) in the coding region of the human PDH E2 gene.

## Claims

### Claim 1

A method for the diagnosis of a polymorphism in PDH E2 in a human, which method comprises determining the sequence of the human at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO: 1 or positions 216 or 349 of PDH E2 protein as defined by the position in SEQ ID NO: 2; and determining the status of the human by reference to polymorphism in PDH E2.

### Claim 2 (depends on 1)

A method according to claim 1 in which the polymorphisms are further defined as:
5 Position Polymorphism Reference 857 T/C SEQ ID NO:1 1255 G/A SEQ ID NO:1 216 Val-Ala SEQ ID NO:2 349 Asp-Asn SEQ ID NO:2

### Claim 3

An isolated nucleic acid comprising any one of the following polymorphisms:
the nucleic acid of SEQ ID NO: 1 with C at position 857 as defined by the positions in SEQ ID NO: 1;
the nucleic acid of SEQ ID NO: 1 with A at position 1255 as defined by the position in SEQ ID NO: 1;
or a complementary strand thereof or an antisense sequence thereto or a fragment thereof of at least 20 bases comprising at least one polymorphism.

### Claim 4

An allele specific primer capable of detecting a PDH E2 gene polymorphism at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO: 1.

### Claim 5

An allele-specific oligonucleotide probe capable of detecting a PDH E2 gene polymorphism at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO: 1.

### Claim 6 (depends on 4, 5)

A diagnostic kit comprising an allele specific oligonucleotide probe as claimed in claim 5 and/or an allele-specific primer as claimed in claim 4.

### Claim 7 (depends on 2)

Use of any polymorphism defined in claim 2 as a genetic marker in a linkage study.

### Claim 8

A method of treating a human in need of treatment with a PDH drug in which the method comprises:
i) diagnosis of a polymorphism in PDH E2 in a human, which method comprises determining the sequence of the human at one or more of positions 857 and 1255 in the PDH E2 gene as defined by the positions in SEQ ID NO: 1 or positions 216 or 349 of PDH E2 protein as defined by the position in SEQ ID NO: 2; and determining the status of the human by reference to polymorphism in the PDH E2; and
ii) administering an effective amount of a PDH drug.

### Claim 9

An allelic variant of the human PDH E2 polypeptide in isolated form having a alanine at position 216 and/or an asparagine at position 349 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 216 and/or position 349.

### Claim 10

An antibody specific for an allelic variant of human PDH E2 polypeptide having a alanine at position 216 and/or an asparagine at position 349 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variants at position 216 and /or position 349.

### Claim 11 (depends on 1, 2)

Use of any polymorphism as defined in claim 1 or 2 in bioinformatic analysis.

### Claim 12 (depends on 11)

A use according to claim 11 comprising a bioinformatic analysis selected from homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis.
